JP2024536001A - レチクロカルビン－３（ｒｃｎ３）バリアント及びインターロイキン－４受容体アルファ（ｉｌ４ｒ）アンタゴニストによる喘息の治療 - Google Patents

レチクロカルビン－３（ｒｃｎ３）バリアント及びインターロイキン－４受容体アルファ（ｉｌ４ｒ）アンタゴニストによる喘息の治療 Download PDF

Info

Publication number
JP2024536001A
JP2024536001A JP2024513821A JP2024513821A JP2024536001A JP 2024536001 A JP2024536001 A JP 2024536001A JP 2024513821 A JP2024513821 A JP 2024513821A JP 2024513821 A JP2024513821 A JP 2024513821A JP 2024536001 A JP2024536001 A JP 2024536001A
Authority
JP
Japan
Prior art keywords
rcn3
nucleic acid
acid molecule
subject
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536001A5 (https=
Inventor
ポールディング、チャールズ
チェン、シャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024536001A publication Critical patent/JP2024536001A/ja
Publication of JP2024536001A5 publication Critical patent/JP2024536001A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2024513821A 2021-09-30 2022-09-27 レチクロカルビン－３（ｒｃｎ３）バリアント及びインターロイキン－４受容体アルファ（ｉｌ４ｒ）アンタゴニストによる喘息の治療 Pending JP2024536001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163250546P 2021-09-30 2021-09-30
US63/250,546 2021-09-30
PCT/US2022/077088 WO2023056254A1 (en) 2021-09-30 2022-09-27 Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists

Publications (2)

Publication Number Publication Date
JP2024536001A true JP2024536001A (ja) 2024-10-04
JP2024536001A5 JP2024536001A5 (https=) 2025-09-10

Family

ID=83902767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513821A Pending JP2024536001A (ja) 2021-09-30 2022-09-27 レチクロカルビン－３（ｒｃｎ３）バリアント及びインターロイキン－４受容体アルファ（ｉｌ４ｒ）アンタゴニストによる喘息の治療

Country Status (9)

Country Link
US (1) US20230151426A1 (https=)
EP (1) EP4409037A1 (https=)
JP (1) JP2024536001A (https=)
KR (1) KR20240067064A (https=)
CN (1) CN117957332A (https=)
CA (1) CA3230302A1 (https=)
IL (1) IL311480A (https=)
MX (1) MX2024003921A (https=)
WO (1) WO2023056254A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos

Also Published As

Publication number Publication date
CN117957332A (zh) 2024-04-30
EP4409037A1 (en) 2024-08-07
KR20240067064A (ko) 2024-05-16
CA3230302A1 (en) 2023-04-06
IL311480A (en) 2024-05-01
MX2024003921A (es) 2024-04-22
WO2023056254A1 (en) 2023-04-06
AU2022356375A1 (en) 2024-03-14
US20230151426A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
IL298930A (en) Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors
JP2026004359A (ja) Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療
US20240102013A1 (en) Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors
CA3244298A1 (en) TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL VARIANTS 2 (TREM2) AND ITS USES IN THE TREATMENT OF ALZHEIMER'S DISEASE
KR20230167355A (ko) Mhc-1-병증 위험 일배체형을 치료하는 물질 및 방법
CN115667548A (zh) 含有Kelch结构域的7B(KLHDC7B)变体及其用途
US20230000897A1 (en) Treatment Of Cerebrovascular Disease With Neurogenic Locus Notch Homolog Protein 3 (NOTCH3) Agents
US20220233569A1 (en) Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors
AU2022356375B2 (en) Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists
US20230151426A1 (en) Reticulocalbin-3 (RCN3) Variants And Treatment Of Asthma With Interleukin-4 Receptor Alpha (IL4R) Antagonists
US20230192864A1 (en) Treatment Of Lung Conditions With Integrin Subunit Alpha 1 (ITGA1) Inhibitors
EP4114975B1 (en) Fascin-2 (fscn2) variant and use thereof
US20230242988A1 (en) Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors
US20210371930A1 (en) Solute Carrier Family 26 Member 5 (SLC26A5) Variants And Uses Thereof
JP2024536491A (ja) 小胞体アミノペプチダーゼ１（ｅｒａｐ１）阻害剤によるぶどう膜炎の治療
US20230027007A1 (en) Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors
JP2024524554A (ja) ピエゾ型機械受容イオンチャネル成分１（ｐｉｅｚｏ１）アゴニストによる静脈瘤の処置
JP2024535110A (ja) Ｒｈｏグアニンヌクレオチド交換因子１２（ＡＲＨＧＥＦ１２）阻害剤による緑内障の治療
JP2024524555A (ja) ヒスチジンアンモニアリアーゼ（ｈａｌ）アゴニストで皮膚癌を治療する方法
US20210189495A1 (en) Adenylate Cyclase 7 (ADCY7) Variants And Uses Thereof
CA3141309A1 (en) Synaptojanin 2 (synj2) variants and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250829